Scholarlink

Background <p>To identify the associations between thymic pathology and the prognosis of myasthenia gravis (MG) patients.</p> Methods <p>In this multicenter retrospective study, 1,254 myasthenia gravis (MG) patients who underwent thymectomy across four clinical centers were included. Participants were categorized by thymic pathology into thymomatous and non-thymomatous groups. Primary outcome was postoperative deterioration. Secondary outcomes comprised the proportion of patients achieving minimal manifestation status (MMS) within the first year after surgery and conversion from ocular MG (OMG) to generalized MG (GMG) within 2&#xa0;years of symptom onset. Subgroup analyses assessed associations between world health organization (WHO) pathological type (both groups) or Masaoka stage (thymoma patients) and prognosis.</p> Results <p>Thymomas were associated with an increased risk of deterioration in both Cox regression (adjusted HR = 1.40 [1.18, 1.66], <i>p</i> &lt; 0.001) and logistic regression analyses (1-year deterioration: adjusted OR = 1.59 [1.15, 2.20], <i>p</i> = 0.005; 3-year deterioration: adjusted OR = 1.40 [1.01, 1.94], <i>p</i> = 0.047). Additionally, thymomas were linked to a higher conversion rate (adjusted OR = 2.37 [1.15, 4.86], <i>p</i> = 0.019). However, thymoma showed no significant association with MMS (adjusted <i>p</i> = 0.682). In the thymoma subgroup, neither pathological type nor Masaoka stage was significantly associated with deterioration (pathological type: 1-year <i>p</i> = 0.069, 3-year <i>p</i> = 0.220; Masaoka stage: 1-year <i>p</i> = 0.944, 3-year <i>p</i> = 0.909), first-year MMS attainment (pathological type: <i>p</i> = 0.067; Masaoka stage: <i>p</i> = 0.579), or conversion rate (pathological type: <i>p</i> = 0.606; Masaoka stage: <i>p</i> = 0.163). Similarly, in the nonthymomatous group, WHO pathological type was not significantly correlated with deterioration (1-year <i>p</i> = 0.806, 3-year <i>p</i> = 0.654), MMS achieved (<i>p</i> = 0.940), or conversion (<i>p</i> = 0.755).</p> Conclusions <p>This study demonstrated an association between thymoma and higher risks of clinical deterioration, which was independent of WHO pathological type or Masaoka stage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Moli Fan,
  • Hao Zhang,
  • Yutong Shi,
  • Xiaoyu Huang,
  • Ying Cui,
  • Zihao Yu,
  • Xiao-He Zhang,
  • Xiao-Jing Zhang,
  • Ying-Ping Xue,
  • Lei Huang,
  • Fu-Dong Shi,
  • Guo-Yan Qi

摘要

Background

To identify the associations between thymic pathology and the prognosis of myasthenia gravis (MG) patients.

Methods

In this multicenter retrospective study, 1,254 myasthenia gravis (MG) patients who underwent thymectomy across four clinical centers were included. Participants were categorized by thymic pathology into thymomatous and non-thymomatous groups. Primary outcome was postoperative deterioration. Secondary outcomes comprised the proportion of patients achieving minimal manifestation status (MMS) within the first year after surgery and conversion from ocular MG (OMG) to generalized MG (GMG) within 2 years of symptom onset. Subgroup analyses assessed associations between world health organization (WHO) pathological type (both groups) or Masaoka stage (thymoma patients) and prognosis.

Results

Thymomas were associated with an increased risk of deterioration in both Cox regression (adjusted HR = 1.40 [1.18, 1.66], p < 0.001) and logistic regression analyses (1-year deterioration: adjusted OR = 1.59 [1.15, 2.20], p = 0.005; 3-year deterioration: adjusted OR = 1.40 [1.01, 1.94], p = 0.047). Additionally, thymomas were linked to a higher conversion rate (adjusted OR = 2.37 [1.15, 4.86], p = 0.019). However, thymoma showed no significant association with MMS (adjusted p = 0.682). In the thymoma subgroup, neither pathological type nor Masaoka stage was significantly associated with deterioration (pathological type: 1-year p = 0.069, 3-year p = 0.220; Masaoka stage: 1-year p = 0.944, 3-year p = 0.909), first-year MMS attainment (pathological type: p = 0.067; Masaoka stage: p = 0.579), or conversion rate (pathological type: p = 0.606; Masaoka stage: p = 0.163). Similarly, in the nonthymomatous group, WHO pathological type was not significantly correlated with deterioration (1-year p = 0.806, 3-year p = 0.654), MMS achieved (p = 0.940), or conversion (p = 0.755).

Conclusions

This study demonstrated an association between thymoma and higher risks of clinical deterioration, which was independent of WHO pathological type or Masaoka stage.